Chemokines Profiling of Patients with Preterm Birth
Table 2
Concentration of chemokines in maternal sera.
Group I— preterm labor
Group II— false preterm labor
Group III— births at term
value*
Dunn’s test***
Chemokines concentration (pg/mL)
Group I—Group II—Group III
Median (min–max)
6Ckine
11539 (2713–77761)
12543 (3226–39407)
13199 (3328–74956)
0.47
Axl
1306 (529.5–7509)
1389 (601.4–3074)
1278 (554.9–2203)
0.96
BTC
8924 (5577–32195)
8246 (5383–18495)
8754 (6103–38241)
0.4
CCL28
13504 (7193–41772)
13959 (7923–78508)
14449 (9270–54187)
0.43
CTACK/CCL27
3831 (1028–93251)
4138 (1006–25364)
4205 (1932–27000)
0.88
CXCL16
2849 (1789–7924)
2844 (1260–13175)
2975 (1976–13875)
0.62
ENA-78/CXCL5
2894 (380.8–16116)
2728 (799.4–19843)
3999 (1187–12908)
0.06
Eotaxin-3
4545 (2229–18529)
4269 (1507–23502)
4845 (3239–19933)
0.28
GCP-2
709.7 (132.1–2507)
743.8 (190–1841)
649.8 (90.1–1334)
0.35
GRO α. β. γ/CXCL1. CXCL2. CXCL3
522.6 (351.4–1187)
464.2 (350.7–891.9)
662.7 (485.1–1686)
<0.0001**
II-III I–III
HCC-1/CCL14
1246 (394.7–3547)
1302 (338.9–3414)
1197 (868.4–2146)
0.59
HCC-4/CCL16
849.2 (452.5–1939)
1222 (550.6–2183)
710.7 (533.9–918.3)
<0.0001**
I-II II-III I–III
IL-9
87505 (41779–323057)
93656 (39866–148290)
94488 (65506–175965)
0.17
IL-17F
1685 (81–25311)
1204 (99.7–20224)
1335 (138.3–17388)
0.40
IL-18 BPa
9087 (2811–28743)
10040 (4294–25752)
11219 (6197–41799)
0.15
IL-28A
279.8 (31.9–1778)
234.6 (43.2–481)
342.3 (42.4–525.6)
0.04**
II-III
IL-29
26560 (10546–105551)
24315 (11423–193283)
30091 (15078–131083)
0.02**
II-III
IL-31
573 (64.8–10512)
721.5 (64.8–31428)
474.3 (84.5–33119)
0.67
IP-10/CXCL10
832.4 (366.8–1936)
985.3 (399.4–2013)
862.0 (524–1256)
0.08
I-TAC/CXCL11
55.65 (14.7–620.5)
31.60 (18.8–215.4)
48.65 (14.1–255.2)
0.005**
I-II
LIF
2368 (378.4–4919)
2894 (814.3–4176)
2689 (1198–3678)
0.39
LIGHT/TNFSF14
149.8 (42.8–768.7)
149.7 (48.7–315.8)
171.4 (82.1–259.4)
0.13
Lymphotactin/XCL1
2814 (1457–9097)
2542 (1070–5303)
2918 (1180–4593)
0.50
MCP-2/CCL8
7.9 (1.9–75.6)
6 (1.3–66.9)
11.55 (3.9–17.4)
0.08
MCP-3/CCL7
54.35 (14.8–657.5)
43.7 (9.6–125)
50.7 (22–448.3)
0.36
MCP-4/CCL13
120.5 (40.7–449.1)
96.3 (14.5–216.7)
118.2 (19–313.4)
0.08
MDC/CCL22
3299 (778.8–9025)
3578 (152.3–9297)
3751 (1736–5840)
0.28
MIF
365.5 (100.3–3214)
330.0 (105–5852)
460.9 (112.2–3347)
0.11
MIP-3α/CCL20
6.33 (1.7–51.9)
3.35 (1–8.8)
6.8 (2.2–11.6)
0.03**
I-II II-III
MIP-3β/CCL19
889.5 (400.6–3476)
860.2 (327.6–11042)
963.2 (568–11621)
0.15
MPIF1/CCL23
2670 (811.7–11855)
2540 (1003–4762)
2562 (1468–13547)
0.44
MSPα
3780 (959.8–31556)
3801 (384.2–36637)
2935 (1014–15452)
0.13
NAP-2/CXCL7
221.4 (103.8–614.7)
267.6 (125.5–614.7)
197.8 (141.6–324.8)
0.016**
II-III
OPN
255.2 (61.9–2243)
272.5 (49.7–703.8)
376.4 (86.8–954.5)
0.24
PARC/CCL18
3217 (1073–7453)
2981 (1061–6378)
3122 (1621–4999)
0.67
PF4
5137 (2564–24892)
5145 (1834–13097)
5251 (1684–11418)
0.81
SDF-1/CXCL12
384.0 (45.7–1842)
329.5 (70.2–701.5)
333.5 (37.5–574.3)
0.52
TARC/CCL17
68.40 (7.5–421.6)
39.25 (3.1–174.7)
98.25 (2.4–409.3)
0.002**
I-II II-III
TECK/CCL25
24077 (5484–52685)
22457 (5431–73659)
29067 (11315–41058)
0.0047**
II-III
TSLP
487.7 (174.1–4804)
395.2 (103.1–7183)
500.9 (108.6–2503)
0.33
* value for Kruskal-Wallis test.
**Statistically significant value of less than 0.05.
***Pairs of groups for which there are statistically significant differences (significance level 0.05).
